57 Start-Up Device Companies Confirmed to Present at Medtech Insight/Windhover Information’s "Investment In Innovation (In3) East” Conference
Event Kicks Off with “Medical Device Investor Day” Symposium, Featuring Presentations by Some of the Biggest Names in the Device Industry
October 22-24, 2008, Boston, MA
Irvine, CA September 3, 2008
Medtech Insight, a division of FDC-Windhover, an Elsevier company, and a leading provider of business information for the medical device industry, has announced that 57 early- to late-stage companies are now confirmed to present at their upcoming “Investment In Innovation (In3) East” conference, being held October 22-24, 2008 at The Westin Copley Place in Boston, MA. Presentation timeslots are now filled and a number of potential presenters are waitlisted for this popular event, designed for those looking to partner, invest and network with the most promising start-up medical technology companies on course to impact the worldwide med device market. Preceding In3 East will be a first-of-its-kind “Medical Device Investor Day” symposium, featuring illuminating presentations by approximately 13 of the most influential large companies in the device space (9 are confirmed to date).
The two-day In3 East event – the company’s 32nd In3 conference – will showcase nearly 60 highly promising start-up med device companies from around the world, presenting to an audience of senior business development and investment executives from the leading medical technology and healthcare investment firms worldwide, for purposes of raising funding or forming strategic partnerships. Presenting companies to date (the majority presenting at an In3 event for the first time) from the U.S., Canada, Europe and Israel include Advanced BioSensors, Inc., AugmentRx Medical, Inc., Axogen, Inc., BioLineRx, Ltd., BoneGrafix, Cardiola, Ltd., CardioMag Imaging, Inc., Ceragenix Pharmaceuticals, Cerapedics, Inc., Cohera Medical, Inc., Core Essence Orthopaedics LLC, CoreSpine Technologies, Curative Biosciences, Inc., Delcath Systems, Inc., DermTech International, eCardio Diagnostics, Endosense SA, EndoSphere Inc., Envisionier Medical Technologies, EyeMarker Systems, Inc., FAST Diagnostics, Genesis Medical Interventional, Inc., Healionics Corporation, HydroCision, Inc., InspireMD, Intellwave, LLC, LifeBond Ltd., LineaGen, Inc., MicroTransponder Inc., Minnow Medical, mNemoscience GmbH, MST (Medical Smart Tools), MTM Laboratories, nContact Surgical, Inc., NeoMend, Inc., Nerites Corporation, Osprey Medical Inc., PEAK Surgical, Inc., Polymedix, Inc., Rosetta Genomics, Sage Technology & Development, Scil Technology GmbH, Sensimed AG, Sentinel Group LLC, Sherlock-NMD, SonoMedix, Spinal Elements, Symbios Medical, TissueGen, Inc., Urovalve, Inc., Victhom Human Bionics Inc., ViOptix Inc., Vivostat A/S, and Xylos Corporation, among several others to be announced.
The single-track In3 East format will include focused 10-minute presentations by a senior executive from each presenting company in one main ballroom, each followed immediately by one-on-one meetings with interested parties in private breakout rooms. The program will also feature a pre-conference panel on Wednesday evening, Oct. 22 hosted by Chris Velis, Chairman and CEO of Medical Capital Advisors, and an informative panel discussion on Thursday morning, Oct. 23, entitled “Stories Behind How Financing Deals Got Done,” with panelists to include David Milne, Managing Partner, SV Life Science Advisers LP; Kevin Connors, General Partner, Spray Venture Partners; and Amir Nashat, General Partner, Polaris Ventures. A presenting company product exhibition and networking reception will take place on Thursday evening. A second interactive panel discussion, “FDA Update: Tips for Smooth and Successful Interactions with CDRH,” will be held on Friday morning, Oct. 24.
In3 East co-sponsors include AdvaMed, Averion, Battelle, Business Wire, Edwards Angell Palmer & Dodge, Invest In Germany, MDMA, Medmarc and The Hartford, Medical Capital Advisors, Push-Med, The MedTech Group, Ronald Trahan Associates, TATRC, and FDC Reports’ The Gray Sheet. Visit www.windhover.com/in3east08 for regularly updated program details.
The Medical Device Investor Day Symposium, being held 8 a.m. to 5 p.m. on Oct. 22, will showcase illuminating presentations by approximately 13 of the most influential large companies in the device space. Senior executives from each of these hand-selected companies will speak candidly on what interests them most in medical device technologies, therapeutic areas, products, and geographic markets. They will also inform our audience about partnering opportunities, how companies can maximize their visibility in front of large company investors, and what role M&A plays at their companies. The nine confirmed presenters for Investor Day to date include: Susan Paquette, Technology Assessment Director, 3M; Paul O'Connell, Vice President, Vascular Interventional Products Group, B. Braun Medical; Albert Lauritano, Director, Business Development, Becton Dickinson (BD); Jim Gilbert, Executive Vice President, Strategy and Business Development, Boston Scientific Corporation; Dennis Crowley, Director Business Development, Covidien; Bob Mellen, VP, Strategic Planning & Business Development, C.R. Bard; Margaret Helms, Director, WW New Business Development, Ethicon/J&J, Shawn McCormick, Director, Corporate Development, Medtronic; and a to-be-announced senior executive from Stryker Corporation.
David Cassak, Managing Partner at Windhover Information, kicks off Investor Day with an opening keynote address on the state of larger medical technology company M&A and deal trends. He will be discussing which investment models for larger companies are working, how larger companies are sustaining growth and what the current and future appetite is for M&A. Investor Day is a must-attend event for those interested in what the leaders of the med device industry are thinking, doing, and planning in terms of investment. The registration rate for Medical Device Investor Day only is $795, or this is discounted to $495 when registering for In3 East at the same time. Visit www.windhover.com/investorday for more information.
Medtech Insight and its parent company, FDC-Windhover, an Elsevier company, have established a reputation as holding the premier forums worldwide for discerning senior executives in the medical device, diagnostics, biotech, and pharmaceutical business development and investment communities to meet and screen promising early-stage life sciences companies in need of funding, acquisition and/or strategic partnership, and to network with key decision makers in the industry. Over 1400 emerging medical technology company presenters and over 7500 attendees have participated at In3 events over the past 7 years.
Upcoming medtech investment and partnering events from Medtech Insight and FDC-Windhover include their “Investment In Innovation (In3) West” conference at The Palazzo in Las Vegas, NV, March 2-4, 2009, followed by “Investment In Innovation (In3) Europe” at the Marriott Rive Gauche Hotel in Paris, April 29-30.